Abstract: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor ?/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).

Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.

Abstract: The present invention relates to mixed metal compounds having pharmaceutical activity, especially as phosphate binders. It also extends to methods of manufacture of those compounds, as well as to pharmaceutical compositions containing such compounds. It further relates to their pharmaceutical use. In particular, the present invention relates to use of compounds of Formula (I): MII1-aMIIIa wherein M? is at least one bivalent metal (i.e. with two positive charges); M1 is at least one trivalent metal (i.e. with three positive charges); and 1>a>0.4.

Abstract: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor ?/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).

Abstract: Computer-implemented methods and systems for classifying documents and freight-truck-transaction documents are described. A method may comprise receiving document data corresponding to a document, at a document classification device, wherein the document data comprises text data. The method may further comprise detecting, at the document classification device, an existence of, or an absence of, one or more predetermined text fields in the document based upon, at least in part, the document data. The method may additionally comprise assigning, at the document classification device, a value to the one or more predetermined text fields based upon, at least in part, the existence of, or the absence of, the one or more predetermined text fields in the document. The method may also comprise determining, at the document classification device, a score for the document based upon, at least in part, values assigned to the one or more predetermined text fields.

Abstract: The invention features multi-specific protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to a disease antigen, immune checkpoint or signaling molecule.

Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.

Abstract: There is provided a granular material comprising (i) at least 50% by weight based on the weight of the granular material of solid water-insoluble mixed metal compound capable of binding phosphate of formula (I): MII1-x.MIIIx(OH)2An?y.zH2O (I) where MII is at least one of magnesium, calcium, lanthanum and cerium; MII is at least iron(III); An is at least one n-valent anion; x=?ny, 0<x?0.67, 0<y?1, and 0?z<10; (ii) from 3 to 12% by weight based on the weight of the granular material of non-chemically bound water, and (iii) no greater than 47% by weight based on the weight of the granular material of excipient.

Abstract: The invention features soluble fusion protein complexes comprising at least two soluble fusion proteins. For example, the first fusion protein is an anti-CD3 antibody covalently linked to an interleukin-15 (IL-15) polypeptide or functional fragment thereof. The second fusion protein comprises a binding domain that recognizes disease antigens, wherein this domain is covalently linked to a soluble interleukin-15 receptor alpha (IL-15R?) polypeptide or a functional fragment thereof. One or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof, and the IL-15 domain of first fusion protein binds to the soluble IL-15R? domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.

Abstract: Systems and methods for displaying a simplified version of a modification of a media content item on a mobile device are provided. The mobile device can receive, via a user interface presented on the mobile device, a request for a desired modification of an original media content item. The mobile device can perform a simplified version of the desired modification of the original media content item. The mobile device can present a preview of the modified media content item in the user interface. The mobile device can transmit, to another computing device, the original media content item with the request for the desired modification.

Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

Abstract: Systems and methods for displaying a simplified version of a modification of a media content item on a mobile device are provided. The mobile device can receive, via a user interface presented on the mobile device, a request for a desired modification of an original media content item. The mobile device can perform a simplified version of the desired modification of the original media content item. The mobile device can present a preview of the modified media content item in the user interface. The mobile device can transmit, to another computing device, the original media content item with the request for the desired modification.

Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

Abstract: The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide or a functional fragment thereof. The second fusion protein is a second biologically active polypeptide covalently linked to a soluble interleukin-15 receptor alpha (IL-15R?) polypeptide or a functional fragment thereof. In the complexes of the invention, one or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof; and the first fusion protein binds to the soluble IL-15R? domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.

Abstract: There is provided a method of producing a mixed metal compound that includes at least Mg2+ and at least Fe3+ having an aluminum content of less than 10000 ppm, having an average crystal size of less than 20 nm (200 ?) comprising the steps of: (a) combining a Mg2+ salt and a Fe3+ salt with Na2CO3 and NaOH to produce a slurry, wherein the pH of the slurry is maintained at from 9.5 to 11, and wherein the Na2CO3 is provided at an excess of 0 to 4.0 moles than is required to complete the reaction (b) subjecting the slurry to mixing under conditions providing a power per unit volume of 0.03 to 1.6 kW/m3 (c) separating the mixed metal compound from the slurry, to obtain a crude product having a dry solid content of at least 10 wt % (d) drying the crude product.

Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making the such proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.

Abstract: The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide or a functional fragment thereof. The second fusion protein is a second biologically active polypeptide covalently linked to a soluble interleukin-15 receptor alpha (IL-15R?) polypeptide or a functional fragment thereof. In the complexes of the invention, one or both of the first and second fusion proteins further includes an immunoglobulin Fc domain or a functional fragment thereof; and the first fusion protein binds to the soluble IL-15R? domain of the second fusion protein to form a soluble fusion protein complex. The invention further provides methods for making and using the complexes of the invention.

Abstract: Systems and methods for facilitating content capturing on a mobile device are provided. The current position of a mobile device is identified during a content capturing preparation stage. The current position of the mobile device can correspond to a first position or a second position. The first position is a preferred position for capturing content as compared to the second position. When the current position of the mobile device corresponds to the second position, a prompt can be provided on the mobile device to instruct a user of the mobile device to move the mobile device to the first position.

Abstract: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor ?/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).

Abstract: The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor ?/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus).